MONMOUTH JUNCTION, NJ–(Marketwired – September 26, 2016) – DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, reported today that the following new patents have been issued or allowed between April and September 2016:
“Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases” in Europe (issued in the United States in February 2014);
“Methods of using miRNA from bodily fluids for early detection and monitoring of Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD)” in the United States, Japan, China, and Australia;
“miRNA-based Universal Screening Test” in Europe.